# The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer

> **NCT06269445** · PHASE4 · UNKNOWN · sponsor: **Sir Run Run Shaw Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Icaritin Combined With Bevacizumab and FOLFIRI

## Key facts

- **NCT ID:** NCT06269445
- **Lead sponsor:** Sir Run Run Shaw Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06269445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06269445, "The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT06269445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*